This anti-TSLP biologic administered by subcutaneous injection was recently approved in clinical practice for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma, irrespective of baseline biomarkers and regardless of the underlying endotype or phenotype [125,126]. This evidence concerns the gene TSLP and asthma.